BHV-7000, A Novel, Selective Kv7.2/7.3 Potassium Channel Activator, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults

• Jason Lerner, M.D.,
• Bharat Awsare, M.D.,
• Heather Sevinsky, M.S.,
• Eric Ashbrenner, M.S.,
• Randall Killingsworth, B.A.,
• Racheal Kendrick, PharmD,
• Emiel Vereycken, M.S.,
• Nigel Colenbier, Ph.D.,
• Caroline Neuray, M.D.,
• Pieter van Mierlo, Ph.D.,
• Jeremy Slater, M.D.,
• David Wyatt, M.D.,
• Irfan Qureshi, M.D.,
• Steven Dworetzky, Ph.D.,
• Michael Bozik, M.D.

Affiliations

Jason Lerner, M.D.

Biohaven Pharmaceuticals

Bharat Awsare, M.D.

Biohaven Pharmaceuticals

Heather Sevinsky, M.S.

Biohaven Pharmaceuticals

Eric Ashbrenner, M.S.

Biohaven Pharmaceuticals

Randall Killingsworth, B.A.

Biohaven Pharmaceuticals

Racheal Kendrick, PharmD

Certara, Inc

Emiel Vereycken, M.S.

Epilog, Clouds of Care NV

Nigel Colenbier, Ph.D.

Epilog, Clouds of Care NV

Caroline Neuray, M.D.

Epilog, Clouds of Care NV

Pieter van Mierlo, Ph.D.

Epilog, Clouds of Care NV

Jeremy Slater, M.D.

Stratus

David Wyatt, M.D.

Syneos Health

Irfan Qureshi, M.D.

Biohaven Pharmaceuticals

Steven Dworetzky, Ph.D.

Biohaven Pharmaceuticals

Michael Bozik, M.D.

Biohaven Pharmaceuticals